Beth Overmoyer
#179,746
Most Influential Person Now
American physician and oncologist
Beth Overmoyer's AcademicInfluence.com Rankings
Beth Overmoyermedical Degrees
Medical
#3754
World Rank
#4262
Historical Rank
Oncology
#272
World Rank
#281
Historical Rank
Beth Overmoyerphilosophy Degrees
Philosophy
#11874
World Rank
#16417
Historical Rank
Logic
#8682
World Rank
#10889
Historical Rank
Download Badge
Medical Philosophy
Why Is Beth Overmoyer Influential?
(Suggest an Edit or Addition)According to Wikipedia, Beth Ann Overmoyer is an American physician and oncologist. She is Director of the Inflammatory Breast Cancer Program at the Dana–Farber Cancer Institute. Early life and education Overmoyer was an undergraduate student in biology and graduated magna cum laude. She was a medical student at the Case Western Reserve University, before moving to the University of Pennsylvania for her internship and medical residence. She became interested in oncology in the late eighties, when she started researching breast cancer at the Hospital of the University of Pennsylvania.
Beth Overmoyer's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. (2005) (1308)
- Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. (2005) (622)
- Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. (2005) (515)
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. (2015) (483)
- A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. (2002) (416)
- Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. (2005) (372)
- Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. (2003) (359)
- The influence of young age on outcome in early stage breast cancer. (1994) (249)
- A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. (2010) (158)
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. (2019) (156)
- Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. (1997) (143)
- Cardiovascular Safety Profile of Combretastatin A4 Phosphate in a Single-Dose Phase I Study in Patients with Advanced Cancer (2004) (128)
- Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. (2008) (125)
- A Vasculature-Targeting Regimen of Preoperative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: Impact on Angiogenic Biomarkers (2009) (99)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (78)
- The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer. (2004) (76)
- Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. (2002) (76)
- International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference (2018) (71)
- Uniformity of liver density and nonheme (storage) iron distribution. (1987) (68)
- Breast Conservation Surgery Achieving ≥ 2 mm Tumor‐Free Margins Results in Decreased Local‐Regional Recurrence Rates (2006) (67)
- Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients (2016) (64)
- The significance of signet ring cells in infiltrating lobular carcinoma of the breast. (1995) (64)
- A phase I, open-label study of lapatinib (GW572016) plus trastuzumab; a clinically active regimen (2005) (60)
- Chemotherapy-related amenorrhea after adjuvant paclitaxel–trastuzumab (APT trial) (2015) (59)
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance) (2016) (59)
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: A Randomized Clinical Trial. (2020) (59)
- Delayed G-CSF after autologous progenitor cell transplantation: a prospective randomized trial (1998) (54)
- Microinvasive Breast Cancer: ER, PR, and HER-2/neu Status and Clinical Outcomes after Breast-Conserving Therapy or Mastectomy (2013) (51)
- Inflammatory Breast Cancer as a Model Disease to Study Tumor Angiogenesis: Results of a Phase IB Trial of Combination SU5416 and Doxorubicin (2007) (47)
- Seven-year (yr) follow-up of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). (2017) (45)
- A phase IB clinical and pharmacokinetic study of the angiogenesis inhibitor SU5416 and paclitaxel in recurrent or metastatic carcinoma of the head and neck (2005) (44)
- Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation (2000) (43)
- Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer (2015) (42)
- What radiologists need to know about diagnosis and treatment of inflammatory breast cancer: a multidisciplinary approach. (2013) (42)
- Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. (2018) (42)
- Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC) (2013) (36)
- Loss of antigenic epitopes as the result of env gene recombination in retrovirus-induced leukemia in immunocompetent mice. (1993) (33)
- Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cance (2004) (33)
- Pegylated liposomal doxorubicin and cyclophosphamide as first-line therapy for patients with metastatic or recurrent breast cancer. (2005) (32)
- 670 Phase III comparison of docetaxel (D)and pacilitaxel (P) in patients with metastatic breast cancer (MBC) (2003) (31)
- Options for the treatment of patients with taxane-refractory metastatic breast cancer. (2008) (29)
- Enobosarm: A targeted therapy for metastatic, androgen receptor positive, breast cancer. (2014) (25)
- Targeting breast cancer through its microenvironment: current status of preclinical and clinical research in finding relevant targets. (2015) (25)
- G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 μ g/kg/day (1997) (25)
- Phase II trial of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer (2005) (24)
- Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial) (2019) (23)
- Toxicity results and early outcome data on a randomized phase II study of docetaxel ± bevacizumab for locally advanced, unresectable breast cancer. (2006) (23)
- Progressive disease after ABMT for Hodgkin’s disease (1997) (22)
- Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management (2015) (22)
- The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer (2017) (20)
- Toxicity and outcome data in a phase II study of weekly docetaxel in combination with erlotinib in recurrent and/or metastatic breast cancer (MBC). (2006) (20)
- Combination chemotherapy for metastatic breast cancer: reaching for the cure. (2003) (20)
- Continuous-infusion granisetron compared to ondansetron for the prevention of nausea and vomiting after high-dose chemotherapy (1998) (20)
- Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC). (2019) (19)
- Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis (2021) (18)
- Phase II study of dose-dense sequential doxorubicin and docetaxel for patients with advanced operable and inoperable breast cancer (2006) (18)
- Inflammatory Breast Cancer: a Separate Entity (2019) (18)
- Clinical Efficacy and Molecular Response Correlates of the WEE1 Inhibitor Adavosertib Combined with Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer (2020) (18)
- Inflammatory breast cancer and development of brain metastases: risk factors and outcomes (2015) (18)
- Rebeccamycin analog for refractory breast cancer: A randomized phase II trial of dosing schedules (2006) (17)
- An analysis of prognostic features in infiltrating lobular carcinoma of the breast. (1995) (17)
- P3-16-05: A Phase II Trial Expansion Cohort of the PARP Inhibitor Veliparib (ABT888) and Temozolomide in BRCA1/2 Associated Metastatic Breast Cancer. (2011) (17)
- Inflammatory breast cancer: novel preoperative therapies. (2010) (16)
- Breast cancer screening. (1999) (16)
- Chemotherapeutic palliative approaches in the treatment of breast cancer. (1995) (15)
- A phase I pharmacokinetic and pharmacodynamic study of SU5416 and Adriamycin in inflammatory breast cancer (2001) (15)
- Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study. (2021) (15)
- Ifosfamide in the treatment of breast cancer. (1996) (14)
- Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer (2021) (14)
- A Pharmacogenetic Prediction Model of Progression‐Free Survival in Breast Cancer using Genome‐Wide Genotyping Data from CALGB 40502 (Alliance) (2018) (13)
- Prospective clinical experience with research biopsies in breast cancer patients (2013) (13)
- A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer. (2012) (13)
- Prevalence of germline variants in inflammatory breast cancer (2019) (13)
- Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference (2017) (13)
- Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium (2019) (12)
- Treatment with adjuvant endocrine therapy for early-stage breast cancer: is it forever? (2015) (12)
- Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study (2021) (12)
- Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine (2009) (11)
- Impact of neoadjuvant therapy on breast conservation rates in triple-negative and HER2-positive breast cancer: Combined results of CALGB 40603 and 40601 (Alliance). (2015) (11)
- Platelet transfusion requirements during autologous peripheral blood progenitor cell transplantation correlate with the pretransplant platelet count (1997) (10)
- A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC). (2020) (10)
- High-dose chemotherapy with autologous stem cell support for breast cancer. (1992) (10)
- G-CSF post-autologous progenitor cell transplantation: a randomized study of 5, 10, and 16 micrograms/kg/day. (1997) (10)
- Murine leukemia virus infection in immunocompetent adult mice. (1993) (10)
- Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer: The Dana‐Farber Cancer Institute's Inflammatory Breast Cancer Program experience (2020) (10)
- Induction of the prosurvival secretory clusterin protein as a marker of response after neoadjuvant docetaxel, with or without bevacizumab in patients with locally advanced breast cancer (2004) (9)
- Abstract P1-13-04: Enobosarm for the treatment of metastatic, estrogen and androgen receptor positive, breast cancer. Final results of the primary endpoint and current progression free survival (2015) (9)
- Phase II study of ruxolitinib , a selective JAK 1 / 2 inhibitor , in patients with metastatic triple-negative breast cancer (2018) (8)
- Discrepancy between FDG-PET/CT and contrast-enhanced CT in the staging of patients with inflammatory breast cancer: implications for treatment planning (2020) (8)
- Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: updated results. (2009) (8)
- Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations (2021) (8)
- Variables associated with the platelet count 6 weeks after autologous peripheral blood progenitor cell transplantation (1998) (8)
- A randomized study of multi-day infusion of autologous peripheral blood progenitor cells (1998) (8)
- A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. (2019) (8)
- Metastasis to the Cervix Uteri 15 Years After Treatment of Lobular Carcinoma of the Breast. (2015) (8)
- Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance) (2017) (7)
- Imaging Androgen Receptors in Breast Cancer with 18F-Fluoro-5α-Dihydrotestosterone PET: A Pilot Study (2021) (7)
- The breast cancer prevention trial (P-1 study). The role of tamoxifen in preventing breast cancer. (1999) (7)
- A Phase II Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma. (2019) (6)
- Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC) (2022) (6)
- HER2-low inflammatory breast cancer: Clinicopathologic features and prognostic implications. (2022) (6)
- An open label, phase II trial of continuous low-irradiance photodynamic therapy (CLIPT) using verteporfin for the treatment of cutaneous breast cancer metastases. (2017) (6)
- Abstract P4-06-01: JAK2/STAT3 activity in inflammatory breast cancer supports the investigation of JAK2 therapeutic targeting (2012) (6)
- Metastatic Cancer to Bone (2006) (6)
- Aggressive Subsets of Metastatic Triple Negative Breast Cancer. (2020) (5)
- Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research (2022) (5)
- Phase II study of ruxolitinib in patients with pStat3+ breast cancer. (2013) (5)
- Phase II trial of neoadjuvant docetaxel with or without bevacizumab in patients with locally advanced breast cance. (2004) (5)
- Prolonged Survival in Patients with Metastatic HER2-Positive Inflammatory Breast Cancer: A Case Report and Review of the Literature (2021) (5)
- The feasibility of using an autologous GM-CSF-secreting breast cancer vaccine to induce immunity in patients with stage II–III and metastatic breast cancers (2022) (4)
- Pure Intralymphatic Invasion in the Absence of Stromal Invasion After Neoadjuvant Therapy: A Rare Pattern of Residual Breast Carcinoma (2018) (4)
- The effects of gonadotropins on metabolism of isolated rat granulosa cells. (1984) (4)
- Abstract P6-12-12: Phase I study of the JAK 1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2 negative metastatic breast cancer (MBC) (2017) (4)
- Characteristics associated with inflammatory breast cancer (IBC): An epidemiologic study from a dedicated IBC program (2020) (4)
- A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC). (2018) (4)
- Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG‐PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade (2019) (4)
- A Phase II study of cabozantinib for metastatic triple-negative breast cancer (TNBC). (2015) (4)
- Personalized Management of Chemotherapy‐Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance) (2019) (4)
- Pegylated Liposomal Doxorubicin (Doxil®) Versus Doxorubicin for First-Line Treatment of Metastatic Breast Cancer (2002) (3)
- A Vasculature-Targeting Regimen of Pre-Operative Docetaxel with or without Bevacizumab for Locally Advanced Breast Cancer: (2010) (3)
- Abstract OT3-05-01: TBCRC 039: Phase II study of combination ruxolitinib (INCB018424) with preoperative chemotherapy for triple negative inflammatory breast cancer (2018) (3)
- Abstract PD8-10: Efficacy and safety of enobosarm, a selective androgen receptor modulator, to target AR in women with advanced ER+/AR+ breast cancer - final results from an international Phase 2 randomized study (2021) (3)
- Phase Ib study of pembrolizumab in combination with trastuzumab emtansine for metastatic HER2-positive breast cancer (2022) (3)
- Effect of cabozantinib treatment on circulating immune cell populations in patients with metastatic triple-negative breast cancer (TNBC). (2016) (3)
- A phase II study of tivantinib (ARQ-197) for metastatic triple-negative breast cancer. (2014) (3)
- Case records of the Massachusetts General Hospital. Case 17-2011. A 49-year-old woman with a mass in the breast and overlying skin changes. (2011) (2)
- Early on-treatment vs pre-treatment tumour transcriptomes as predictors of response to neoadjuvant therapy for HER2-positive inflammatory breast cancer (2019) (2)
- Incidence, characteristics, and management of central nervous system metastases in patients with inflammatory breast cancer (2022) (2)
- Abstract P6-14-08: Risk factors for developing inflammatory breast cancer: Unique trends among a single patient population (2015) (2)
- Chemotherapy in the management of breast cancer. (1995) (2)
- Dermal Lymphatic Invasion, Survival, and Time to Recurrence or Progression in Inflammatory Breast Cancer (2021) (2)
- Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC) (2021) (2)
- Inflammatory breast cancer (2014) (2)
- Abstract PD3-08: Assessment of the tumor immune environment in inflammatory breast cancer treated with neoadjuvant dual-HER2 blockade (2019) (2)
- Abstract P6-18-02: Patterns of breast reconstruction in patients diagnosed with inflammatory breast cancer (2016) (2)
- Abstract P3-09-10: A phase II study of nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer (mTNBC) (2020) (2)
- Abstract OT2-01-06: Phase 2 open label, multinational, randomized, parallel design study investigating the efficacy and safety of GTx-024 on metastatic (MET) or locally advanced (LA) ER+/AR+ breast cancer (BC) in postmenopausal (PM) women (2016) (2)
- Abstract P5-11-04: A phase I/IIb study of palbociclib (PALBO) plus everolimus (EVE) and exemestane (EXE) in hormone-receptor positive (HR+)/HER2- metastatic breast cancer (MBC) after progression on a CDK4/6 inhibitor (CDK4/6i): Results of the phase II study (2020) (2)
- Metabolic characterization of inflammatory breast cancer (IBC) with baseline FDG-PET/CT: Relationship with histopathology, hormone receptor status, and pathologic response after neoadjuvant chemotherapy. (2013) (2)
- Inflammatory breast cancer appearance at presentation is associated with overall survival (2021) (2)
- Abstract OT2-01-07: A phase 2 open label, multi-center, multinational study investigating the efficacy and safety of GTx-024 on advanced, androgen receptor-positive triple negative breast cancer (AR+ TNBC) (2016) (2)
- Rebeccamycin analog for refractory breast cancer: a randomized phase II trial (2004) (2)
- Early on-treatment transcriptional profiling as a tool for improving pathological response prediction in HER2-positive inflammatory breast cancer (2022) (1)
- Abstract P6-15-11: Weekly paclitaxel, pertuzumab and trastuzumab (TPH) neoadjuvant therapy for HER2 positive inflammatory breast cancer (2018) (1)
- Genetics and Gynecological Cancer (2013) (1)
- Abstract P4-01-17: Aggressive subgroups of metastatic triple-negative breast cancer: Inflammatory breast cancer and young patients in the Dana-Farber cell-free DNA cohort (2019) (1)
- MRI Changes in Breast Skin Following Preoperative Therapy for Patients with Inflammatory Breast Cancer. (2021) (1)
- 18PFirst stage of an on-going phase 2, open label, international, randomized, parallel design study investigating efficacy + safety of GTx-024 for advanced ER+/AR+ breast cancer (BC) (2017) (1)
- Abstract OT2-04-01: An open label, phase II trial of continuous low-irradiance photodynamic therapy (CLIPT) using verteporfin for the treatment of cutaneous breast cancer metastases (2018) (1)
- Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study (2021) (1)
- Computed tomographic assessment of lean body mass in patients on selective androgen receptor modulator. (2019) (1)
- Abstract CT050: Expansion cohort of Phase I study of oral sapacitabine and oral seliciclib in patients with metastatic breast cancer andBRCA1/2mutations (2019) (1)
- JAK–STAT Signaling in Inflammatory Breast Cancer Enables Chemotherapy-Resistant Cell States (2022) (1)
- Correction to: Inflammatory breast cancer defined: proposed common diagnostic criteria to guide treatment and research (2022) (1)
- Vocal fold paralysis on positron emission tomography-CT (2017) (1)
- Abstract P5-02-01: Discrepancy between CT and FDG-PET/CT in the staging of patients with inflammatory breast cancer: Implications for radiation therapy treatment planning (2012) (1)
- Trastuzumab-associated cardiac dysfunction (2005) (1)
- Abstract OT1-1-07: Phase II trial of paclitaxel combined with trastuzumab and pertuzumab as preoperative therapy for HER2 positive inflammatory breast cancer (2013) (0)
- American Society of Breast Disease Policy Statement on The Use of Breast Magnetic Resonance Imaging (2008) (0)
- Feasibility and Outcomes of Concurrent Paclitaxel Chemotherapy and Radiotherapy for Node-positive Stage II-III Breast Cancer (2008) (0)
- Inflammatory Breast Cancer and Brain Metastases: Risk Factors and Outcomes (2015) (0)
- Abstract PS10-34: Clinical outcomes inde novometastatic HER2-positive inflammatory breast cancer (2021) (0)
- Abstract P3-10-06: Patterns of failure in patients with inflammatory breast cancer: the case for aggressive local/regional treatment (2012) (0)
- Abstract PS14-21: Refining loco-regional therapy for inflammatory breast cancer protocol in progress (2021) (0)
- Abstract P6-15-02: Automated tissue dissection of dermal lymphatic emboli in inflammatory breast cancer enhances accuracy of transcriptional analysis (2020) (0)
- Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer (2018) (0)
- Abstract P5-17-01: Patient-derived organoid models of inflammatory breast cancer (2019) (0)
- Abstract OT1-01-07: A phase 2 study of eribulin followed by doxorubicin and cyclophosphamide as preoperative therapy for HER2-negative inflammatory breast cancer (2017) (0)
- Commentary (Overmoyer): Breast Cancer During Pregnancy (2001) (0)
- Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance) (2017) (0)
- Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Local-Regional Management (2014) (0)
- Abstract P4-07-14: Long-term Outcomes After 1 or 2-3 Lines of Neoadjuvant Therapy in Stage III Inflammatory Breast Cancer (2023) (0)
- Gene Expression Changes Predict Acute and Late Toxicity to Combined PARP1 Inhibition and Radiation (RT) in High Risk Breast Cancer Patients- Results of the Biomarker Analysis of TBCRC 024 (2018) (0)
- Genomic and Transcriptomic Determinants of Resistance to CDK4/6 Inhibitors and Response to Combined Exemestane plus Everolimus and Palbociclib in Patients with Metastatic Hormone Receptor Positive Breast Cancer (2022) (0)
- Abstract P2-15-03: A Phase Ib Study of an adjuvant GM-CSF-Secreting Breast Cancer Vaccine (2015) (0)
- A phase I trial evaluating the safety and immunogenicity of a HER-2 protein vaccine in patients with breast cancer (2004) (0)
- Abstract P6-14-09: Clinical outcomes of triple negative inflammatory breast cancer treated with contemporary anthracycline and taxane preoperative therapy support further investigation of therapeutic targets (2015) (0)
- Abstract P3-08-05: Chemotherapy-related amenorrhea on adjuvant paclitaxel-trastuzumab (APT trial) (2013) (0)
- A randomized trial of a clinic-based weight loss intervention in cancer survivors. (2016) (0)
- Abstract OT2-02-03: Pilot study of zirconium-89 bevacizumab positron emission tomography for imaging angiogenesis in patients with inflammatory breast carcinoma receiving preoperative chemotherapy (2017) (0)
- Excellent Local Control in an Updated Analysis of Concurrent Chemoradiation for Node-positive Breast Cancer Treated with Breast Conserving Surgery (2011) (0)
- The influence of age on outcome in early state breast cancer (1993) (0)
- Abstract PD5-02: PD5-02 An Organoid Model System to Study Resistance Mechanisms, Predictive Biomarkers, and New Strategies to Overcome Therapeutic Resistance in Early-Stage Triple-Negative Breast Cancer (2023) (0)
- Abstract P6-18-03: Tumor profiling of inflammatory breast cancer: Advancing the tools needed for precision medicine (2016) (0)
- Abstract P6-12-05: The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer (2013) (0)
- Phase II Trial of Veliparib and Temozolomide in Metastatic Breast Cancer Patients With and Without BRCA1/2mutations (2021) (0)
- Adjuvant Versus Neoadjuvant Systemic Therapy (2021) (0)
- Future Advances in Chemotherapy for Breast Cancer (2009) (0)
- Prospective clinical experience with research biopsies in breast cancer patients. (2013) (0)
- Cosmetic Outcome and Pulmonary Function After Definitive Radiation with Concurrent Paclitaxel Chemotherapy for Node-Positive Stage II-III Breast Cancer (2005) (0)
- Abstract P6-15-03: Inflammatory breast cancer (IBC) defined: Proposed common diagnostic criteria and scoring - Moving beyond the subjective ‘clinical diagnosis’ of IBC to advance research (2020) (0)
- Copy Number Variation in Inflammatory Breast Cancer (2023) (0)
- Title Influence of Multidisciplinary Breast Cancer Tumor Board Presentations on Breast Cancer Treatment Student Presenter Stacy Banerjee Co-Workers and Collaborators (2006) (0)
- Abstract P6-09-10: Association of dermal lymphatic involvement and survival in inflammatory breast cancer (2019) (0)
- A Phase II study of IncelTM (biricodar, VX-710) in combination with paclitaxel in women with advanced breast cancer refractory to paclitaxel (1999) (0)
- Abstract PD13-06: Incidence and management of central nervous system metastases in patients with inflammatory breast cancer (2021) (0)
- Abstract PS14-04: A picture worth a thousand words - “classic” inflammatory breast cancer (IBC) appearance associated with overall survival (2021) (0)
- Abstract P5-21-10: Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer (2018) (0)
- New Treatments for Metastatic Breast Cancer (2018) (0)
- Phase I pharmacokinetic trial of docetaxel and thalidomide: A regimen based on anti-angiogenic therapeutic principles. (2004) (0)
- 100P Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, in patients with metastatic AR+/ER+ breast cancer resistant to estrogen receptor targeted agents and CDK 4/6 inhibitor in a phase II clinical study (2021) (0)
- Phase I pharmacokinetic trial of docetaxel and thalidomide: A regimen based on anti-angiogenic therapeutic principles (2004) (0)
- Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients. (2021) (0)
- Abstract P2-12-18: A phase 2 study of neoadjuvant systemic therapy with eribulin followed by doxorubicin and cyclophosphamide for HER2-negative inflammatory breast cancer (2022) (0)
- Abstract P4-02-08: MRI changes in breast skin following preoperative therapy for inflammatory breast cancer (IBC) (2016) (0)
- Phase II study of weekly administration of docetaxel (D) in combination with the epidermal growth factor receptor (EGFR) inhibitor erlotinib (E) in metastatic breast cancer (MBC). (2009) (0)
- 206P HER2-low inflammatory breast cancer (IBC): Clinicopathologic features and prognostic implications (2022) (0)
- Regional Chemotherapy for Meningeal Involvement with Breast Cancer (2000) (0)
- Should All Patients with Inflammatory Breast Cancer Undergo Autologous Stem Cell Transplant (2000) (0)
- Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. (2004) (0)
- First-line ribociclib 1 letrozole in HR1, HER2– ABC: Efficacy by baseline tumor markers (2017) (0)
- Abstract P3-10-08: A phase II study of cisplatin and the Wee1 inhibitor adavosertib in metastatic triple-negative breast cancer (mTNBC) (2020) (0)
This paper list is powered by the following services:
Other Resources About Beth Overmoyer
What Schools Are Affiliated With Beth Overmoyer?
Beth Overmoyer is affiliated with the following schools:
